HUP0001528A2 - Szulfonil-karbamid és glitazon szinergetikus kombinációja diabétesz kezelésére - Google Patents
Szulfonil-karbamid és glitazon szinergetikus kombinációja diabétesz kezeléséreInfo
- Publication number
- HUP0001528A2 HUP0001528A2 HU0001528A HUP0001528A HUP0001528A2 HU P0001528 A2 HUP0001528 A2 HU P0001528A2 HU 0001528 A HU0001528 A HU 0001528A HU P0001528 A HUP0001528 A HU P0001528A HU P0001528 A2 HUP0001528 A2 HU P0001528A2
- Authority
- HU
- Hungary
- Prior art keywords
- sulfonylurea
- glitazone
- diabetes
- combinations
- therapy
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 230000002195 synergetic effect Effects 0.000 title abstract 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 abstract 7
- 229940100389 Sulfonylurea Drugs 0.000 abstract 6
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical class C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 3
- 206010022489 Insulin Resistance Diseases 0.000 abstract 2
- 238000009097 single-agent therapy Methods 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- -1 glitazone compound Chemical class 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000002641 glycemic effect Effects 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 238000004448 titration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A jelen találmány diabéteszellenes szulfonil-karbamid vegyületek ésglitazon vegyületek kombinációjára, és ilyen kombinációk diabéteszkezelésére történő alkalmazására vonatkozik. A II típusú diabéteszt azinzulinrezisztencia mellett főként a glükóz stimulusra adott csökkenthasnyálmirigy válasz jelzi. Az inzulinrezisztencia javítása - egyglitazon vegyület adagolásával - nagy előnnyel jár, amikor egyfolyamatban levő, inzulinfelszabadulás stimulálására alkalmas (példáulszulfonilkarbamid), terápiával kapcsolják össze. A glitazon ésszulfonilkarbamid kombinációs terápia biztonságosnak és jóltorelálhatónak mutatkozik és a glikémiás kontrollban szignifikáns ésszinergetikus javulást eredményezhet. A szulfonil-karbamid maximálisdózisaival kezelt betegeket nem szabad glitazon monoterápiáraátállítani. A monoterápiát, amennyiben javallott, csak a szulfonil-karbamid dózis lefelé titrálásával szabad elérni. A vizsgálateredményeinek alkalmazása nem korlátozódhat olyan betegekre, akikesetében a maximális dózisú szulfonil-karbamid terápia nem hatásos,hanem a szulfonil-karbamid kisebb dózisaival kezelt betegekre iskiterjeszthető. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3822497P | 1997-02-19 | 1997-02-19 | |
PCT/US1997/021996 WO1998036755A1 (en) | 1997-02-19 | 1997-12-01 | Sulfonylurea-glitazone synergistic combinations for diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0001528A2 true HUP0001528A2 (hu) | 2000-11-28 |
HUP0001528A3 HUP0001528A3 (en) | 2000-12-28 |
Family
ID=21898725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0001528A HUP0001528A3 (en) | 1997-02-19 | 1997-12-01 | Sulfonylurea-glitazone synergic combinations for diabetes |
Country Status (29)
Country | Link |
---|---|
US (2) | US5859037A (hu) |
EP (1) | EP0957923A1 (hu) |
JP (1) | JP2001512478A (hu) |
KR (1) | KR20000071179A (hu) |
CN (1) | CN1244801A (hu) |
AR (1) | AR011829A1 (hu) |
AU (1) | AU741215B2 (hu) |
BG (1) | BG103671A (hu) |
BR (1) | BR9714505A (hu) |
CA (1) | CA2272478A1 (hu) |
CZ (1) | CZ289299A3 (hu) |
EA (1) | EA199900725A1 (hu) |
EE (1) | EE9900345A (hu) |
GT (1) | GT199800037A (hu) |
HN (1) | HN1997000167A (hu) |
HU (1) | HUP0001528A3 (hu) |
IL (1) | IL130027A (hu) |
IS (1) | IS5058A (hu) |
NO (1) | NO993982D0 (hu) |
NZ (1) | NZ336002A (hu) |
PA (1) | PA8447401A1 (hu) |
PE (1) | PE74399A1 (hu) |
PL (1) | PL335166A1 (hu) |
SK (1) | SK111899A3 (hu) |
SV (1) | SV1998000010A (hu) |
TR (1) | TR199902033T2 (hu) |
UY (1) | UY24893A1 (hu) |
WO (1) | WO1998036755A1 (hu) |
ZA (1) | ZA981343B (hu) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
ATE355840T1 (de) * | 1997-06-18 | 2007-03-15 | Smithkline Beecham Plc | Behandlung der diabetes mit thiazolidindione und metformin |
US20020004515A1 (en) * | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
US20010049380A1 (en) * | 1997-06-18 | 2001-12-06 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and sulphonylurea |
CN1168451C (zh) * | 1997-06-18 | 2004-09-29 | 史密丝克莱恩比彻姆有限公司 | 噻唑烷二酮和磺酰脲组合物在制备治疗糖尿病的药物中的用途 |
GB9715306D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
US7105552B2 (en) * | 1998-05-08 | 2006-09-12 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
US7045519B2 (en) * | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
EP1087963B1 (en) | 1998-06-19 | 2004-08-25 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
GB9824893D0 (en) * | 1998-11-12 | 1999-01-06 | Smithkline Beckman Corp | Novel method of treatment |
US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
WO2000038666A2 (en) * | 1998-12-24 | 2000-07-06 | Metabasis Therapeutics, Inc. | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES |
US7001746B1 (en) * | 1999-01-29 | 2006-02-21 | Artecel Sciences, Inc. | Methods and compositions for the differentiation of human preadipocytes into adipocytes |
ATE364696T1 (de) * | 1999-03-15 | 2007-07-15 | Univ British Columbia | Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts |
US7407978B2 (en) * | 1999-04-06 | 2008-08-05 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
US7563775B2 (en) * | 2000-11-01 | 2009-07-21 | Betty C. Villafuerte | Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes |
US20060154864A1 (en) * | 1999-11-01 | 2006-07-13 | Emory University | Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same |
FR2802814B1 (fr) * | 1999-12-23 | 2002-02-22 | Aventis Pharma Sa | Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees |
DK1145717T3 (da) * | 2000-04-13 | 2004-08-02 | Pfizer Prod Inc | Synergistisk virkning af glyburid og milrinon |
GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
KR200249057Y1 (ko) * | 2001-03-22 | 2001-10-19 | 김진환 | 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치 |
US6492339B1 (en) | 2001-05-23 | 2002-12-10 | Insmed, Incorporated | Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof |
SE0101982D0 (sv) * | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | Pharmaceutical combination |
US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
KR20120034211A (ko) | 2002-09-20 | 2012-04-10 | 안드렉스 랩스 엘엘씨 | 약제학적 정제 |
US9060941B2 (en) * | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US20040147564A1 (en) * | 2003-01-29 | 2004-07-29 | Rao Vinay U. | Combinations of glimepiride and the thiazolidinedione for treatment of diabetes |
AU2004285354B2 (en) | 2003-10-31 | 2009-09-17 | Takeda Pharmaceutical Company Limited | Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
MXPA04009236A (es) * | 2004-09-23 | 2006-03-27 | Jorge Luis Rosado Loria | Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades. |
WO2006074278A2 (en) * | 2005-01-05 | 2006-07-13 | Mitsunori Ono | Compositions for treating diabetes or obesity |
US20090227493A1 (en) * | 2005-05-27 | 2009-09-10 | Daiichi Sankyo Company, Limited | Combined drug for treating diabetes |
US20090170762A1 (en) * | 2005-09-08 | 2009-07-02 | Uutech Limited | Treatment of Diabetes Related Obesity |
CA2623412A1 (en) * | 2005-09-08 | 2007-03-15 | Uutech Limited | Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
US8440695B2 (en) * | 2005-11-09 | 2013-05-14 | St Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
MXPA05013220A (es) * | 2005-12-06 | 2007-06-05 | Leopoldo De Jesus Espinosa Abdala | Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2. |
RU2426530C2 (ru) | 2005-12-22 | 2011-08-20 | Такеда Фармасьютикал Компани Лимитед | Твердый препарат |
WO2008026668A1 (fr) * | 2006-08-31 | 2008-03-06 | Daiichi Sankyo Company, Limited | Composition médicale contenant un agent d'amélioration de la résistance à l'insuline |
CN104163864B (zh) | 2007-03-30 | 2017-08-01 | Ambrx公司 | 经修饰fgf‑21多肽和其用途 |
PT2868315T (pt) | 2007-12-04 | 2017-09-04 | Remedy Pharmaceuticals Inc | Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos |
FR2928836B1 (fr) * | 2008-03-21 | 2011-08-26 | Servier Lab | Forme galenique secable permettant une liberation modifiee du principe actif |
KR20210123406A (ko) | 2008-12-04 | 2021-10-13 | 충시 위 | 고투과력을 가진 조성물 및 이의 적용 |
US20110065756A1 (en) * | 2009-09-17 | 2011-03-17 | De Taeye Bart M | Methods and compositions for treatment of obesity-related diseases |
US9492422B2 (en) | 2009-11-13 | 2016-11-15 | Toray Industries, Inc. | Therapeutic or prophylactic agent for diabetes |
US9241952B2 (en) | 2010-05-24 | 2016-01-26 | Ozstar Therapeutics Pty Ltd | Method of treating type II diabetes, hyperglycemia or hypoglycemia by administering a synergistic combination of a sulphonylurea and inulin |
EP2665433B1 (en) | 2011-01-19 | 2021-03-10 | Fractyl Laboratories Inc. | Devices for the treatment of tissue |
CN104244958B (zh) * | 2011-11-23 | 2017-11-17 | 澳星医疗私人有限公司 | 改进的协同抗糖尿病组合物 |
CN103159651B (zh) * | 2011-12-14 | 2015-06-17 | 安徽贝克联合制药有限公司 | 磺酰脲胍及其制备方法和用途 |
WO2013130655A1 (en) | 2012-02-27 | 2013-09-06 | Fractyl Laboratories, Inc. | Heat ablation systems, devices and methods for the treatment of tissue |
JP6235559B2 (ja) | 2012-04-19 | 2017-11-22 | フラクティル ラボラトリーズ インコーポレイテッド | 組織拡張デバイス、システムおよび方法 |
EP2879605A4 (en) | 2012-07-30 | 2016-04-06 | Fractyl Lab Inc | ELECTRICITY CONTROL SYSTEMS, DEVICES AND METHOD FOR TREATMENT OF TISSUE |
EP2882362B1 (en) | 2012-08-09 | 2024-01-03 | Fractyl Health, Inc. | Ablation systems, devices and methods for the treatment of tissue |
EP2903626A4 (en) | 2012-10-05 | 2016-10-19 | Fractyl Lab Inc | METHODS, SYSTEMS AND DEVICES FOR CARRYING OUT MULTIPLE TREATMENTS OF A PATIENT |
WO2014197632A2 (en) | 2013-06-04 | 2014-12-11 | Fractyl Laboratories, Inc. | Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract |
WO2015038973A1 (en) | 2013-09-12 | 2015-03-19 | Fractyl Laboratories, Inc. | Systems, methods and devices for treatment of target tissue |
EP3071286B1 (en) | 2013-11-22 | 2024-01-03 | Fractyl Health, Inc. | Systems for the creation of a therapeutic restriction in the gastrointestinal tract |
US10959774B2 (en) | 2014-03-24 | 2021-03-30 | Fractyl Laboratories, Inc. | Injectate delivery devices, systems and methods |
US9757535B2 (en) | 2014-07-16 | 2017-09-12 | Fractyl Laboratories, Inc. | Systems, devices and methods for performing medical procedures in the intestine |
WO2016011269A1 (en) * | 2014-07-16 | 2016-01-21 | Fractyl Laboratories, Inc. | Methods and systems for treating diabetes and related diseases and disorders |
US11185367B2 (en) | 2014-07-16 | 2021-11-30 | Fractyl Health, Inc. | Methods and systems for treating diabetes and related diseases and disorders |
KR20240024362A (ko) | 2014-10-24 | 2024-02-23 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 fgf-21 폴리펩티드 및 그의 용도 |
CN108079000A (zh) * | 2018-02-01 | 2018-05-29 | 湖南博隽生物医药有限公司 | 一种治疗糖尿病的药物组合物及其制备方法 |
WO2021102423A1 (en) * | 2019-11-22 | 2021-05-27 | Brown University | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5917052A (en) * | 1994-09-28 | 1999-06-29 | Shaman Pharmaceuticals, Inc. | Hypoglycemic agent from cryptolepis |
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
NO318765B1 (no) * | 1995-07-03 | 2005-05-02 | Sankyo Co | Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner. |
US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
-
1997
- 1997-11-13 US US08/970,057 patent/US5859037A/en not_active Expired - Fee Related
- 1997-12-01 EA EA199900725A patent/EA199900725A1/ru unknown
- 1997-12-01 CN CN97181434A patent/CN1244801A/zh active Pending
- 1997-12-01 EE EEP199900345A patent/EE9900345A/xx unknown
- 1997-12-01 AU AU55908/98A patent/AU741215B2/en not_active Ceased
- 1997-12-01 KR KR1019997007469A patent/KR20000071179A/ko not_active Application Discontinuation
- 1997-12-01 PL PL97335166A patent/PL335166A1/xx unknown
- 1997-12-01 CZ CZ992892A patent/CZ289299A3/cs unknown
- 1997-12-01 EP EP97952250A patent/EP0957923A1/en not_active Withdrawn
- 1997-12-01 IL IL13002797A patent/IL130027A/xx not_active IP Right Cessation
- 1997-12-01 SK SK1118-99A patent/SK111899A3/sk unknown
- 1997-12-01 HU HU0001528A patent/HUP0001528A3/hu unknown
- 1997-12-01 BR BR9714505A patent/BR9714505A/pt not_active Application Discontinuation
- 1997-12-01 TR TR1999/02033T patent/TR199902033T2/xx unknown
- 1997-12-01 NZ NZ336002A patent/NZ336002A/en unknown
- 1997-12-01 JP JP53661198A patent/JP2001512478A/ja not_active Abandoned
- 1997-12-01 CA CA002272478A patent/CA2272478A1/en not_active Abandoned
- 1997-12-01 WO PCT/US1997/021996 patent/WO1998036755A1/en not_active Application Discontinuation
- 1997-12-30 HN HN1997000167A patent/HN1997000167A/es unknown
-
1998
- 1998-01-22 SV SV1998000010A patent/SV1998000010A/es active IP Right Grant
- 1998-02-17 UY UY24893A patent/UY24893A1/es not_active Application Discontinuation
- 1998-02-18 AR ARP980100723A patent/AR011829A1/es unknown
- 1998-02-18 PE PE1998000113A patent/PE74399A1/es not_active Application Discontinuation
- 1998-02-18 GT GT199800037A patent/GT199800037A/es unknown
- 1998-02-18 ZA ZA981343A patent/ZA981343B/xx unknown
- 1998-02-18 PA PA19988447401A patent/PA8447401A1/es unknown
- 1998-10-16 US US09/173,911 patent/US5972973A/en not_active Expired - Fee Related
-
1999
- 1999-05-27 IS IS5058A patent/IS5058A/is unknown
- 1999-08-18 NO NO993982A patent/NO993982D0/no not_active Application Discontinuation
- 1999-08-19 BG BG103671A patent/BG103671A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
IL130027A0 (en) | 2000-02-29 |
BG103671A (en) | 2000-04-28 |
NO993982L (no) | 1999-08-18 |
PA8447401A1 (es) | 2001-12-14 |
AU741215B2 (en) | 2001-11-29 |
BR9714505A (pt) | 2000-03-21 |
IS5058A (is) | 1999-05-27 |
US5972973A (en) | 1999-10-26 |
TR199902033T2 (xx) | 2000-02-21 |
NZ336002A (en) | 2002-03-28 |
GT199800037A (es) | 1999-08-12 |
AU5590898A (en) | 1998-09-09 |
HUP0001528A3 (en) | 2000-12-28 |
US5859037A (en) | 1999-01-12 |
UY24893A1 (es) | 1998-07-10 |
PL335166A1 (en) | 2000-04-10 |
ZA981343B (en) | 1998-11-16 |
IL130027A (en) | 2005-09-25 |
CA2272478A1 (en) | 1998-08-27 |
JP2001512478A (ja) | 2001-08-21 |
SV1998000010A (es) | 1999-02-02 |
NO993982D0 (no) | 1999-08-18 |
CZ289299A3 (cs) | 1999-11-17 |
AR011829A1 (es) | 2000-09-13 |
EA199900725A1 (ru) | 2000-04-24 |
EP0957923A1 (en) | 1999-11-24 |
PE74399A1 (es) | 1999-08-20 |
HN1997000167A (es) | 1999-02-09 |
KR20000071179A (ko) | 2000-11-25 |
CN1244801A (zh) | 2000-02-16 |
SK111899A3 (en) | 2000-09-12 |
WO1998036755A1 (en) | 1998-08-27 |
EE9900345A (et) | 2000-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0001528A2 (hu) | Szulfonil-karbamid és glitazon szinergetikus kombinációja diabétesz kezelésére | |
DE69836352D1 (de) | Transdermales therapeutisches Pflaster mit Capsaicin und seinen Analogen | |
TR200001892T2 (tr) | Monomer cinsi ensülin analogları ve bunların kullanımı. | |
PT913156E (pt) | Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia | |
MY132626A (en) | CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS | |
CY1112034T1 (el) | Μονοδιασπαρμενα μειγματα και μεθοδοι για την θεραπευτικη αγωγη του διαβητη | |
BRPI0502691A (pt) | composição farmacêutica para o controle da glicose no sangue de pacientes com diabetes tipo 2 | |
MY155270A (en) | Use of glp-1 or analogs in treatment of stroke | |
WO2002029087A3 (en) | Use of lymphangiogenic agents to treat lymphatic disorders | |
EP0322226A3 (en) | Site-directed mutagenesis modified glycoprotein hormones and methods of use | |
KR950703353A (ko) | 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus) | |
KR890004690A (ko) | 당뇨병의 치료를 위한 베자피브레이드의 용도 | |
WO2002058720A3 (en) | Angiogenically effective unit dose of fgf-2 and method of use | |
LT2006024A (en) | Tetrapeptide regulating blood glucose level in diabetes mellitus | |
NO20000007D0 (no) | Anvendelse av veksthormon i sammensetninger til behandling av insulinresistens i hjertet samt for å oeke proteinkinase-B(PKB)- aktivitet | |
AU6102801A (en) | Method of preventing or treating diabetes | |
KR900701311A (ko) | 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법 | |
TR200000728T2 (tr) | Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı. | |
Ignatov et al. | The analgetic activity of antidepressants and their influence on the pain-relieving effect of acupuncture | |
Walling | Adolescent diabetes and use of insulin-like growth-factor-1. | |
Klinghardt | BDORT and the subconscious mind | |
ATE328604T1 (de) | Verwendung von wachstumshormon in niederen dosen | |
姚尊华 et al. | OBSERVATION ON 52 CASES OF PARALYSIS OF COMMON PERONEAL NERVE TREATED BY ACUPUNCTURE AND PLUM-BLOSSOM NEEDLING | |
Soboleva | Evaluation of factors providing oxygen of the tissues in miners with vibration disease treated by hyperbaric oxygenation. | |
周荣兴 et al. | THE EFFECT OF ACUPUNCTURE ON THE PHAGOCYTIC ACTIVITY OF HUMAN LEUKOCYTES |